Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
Background and objective: Lenvatinib showed promising results in a subgroup of patients with poorly differentiated thyroid carcinoma (PDTC) in the SELEC T trial. Our aim was to report the effectiveness and tolerability of lenvatinib in our s eries of PDTC patients. Methods: Medical records of eigh...
| Príomhchruthaitheoirí: | , , , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Bioscientifica
2023-04-01
|
| Sraith: | European Thyroid Journal |
| Ábhair: | |
| Rochtain ar líne: | https://etj.bioscientifica.com/view/journals/etj/12/2/ETJ-23-0003.xml |